Anemia and erythropoietin treatment in chronic kidney diseases

Minerva Urologica e Nefrologica

Volumn 57, Issue 1, 2005, Pages 23-31

  Santoro, A ^a   Canova, C ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Anemia; Erythropoietin; Kidney failure

Indexed keywords

AUTOANTIBODY; ERYTHROPOIETIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONTROLLED STUDY; DIALYSIS; ERYTHROID PRECURSOR CELL; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PURE RED CELL ANEMIA; QUALITY OF LIFE; REVIEW; RISK FACTOR;

ANEMIA; ERYTHROPOIETIN, RECOMBINANT; HUMANS; KIDNEY FAILURE, CHRONIC; QUALITY OF LIFE; RED-CELL APLASIA, PURE;

EID: 21344456195     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Dallman PR, Looker AC, Johnson CL, Carrol M. Influence of age on laboratory criteria for the diagnosis of iron deficiency anemia and iron deficiency in infants and children. In: Hallberg L, Asp NG editors. Iron nutrition in health and disease. London, UK: Libbey; 1996. p. 65-74.
2. Levin A, Thompson C, Either J, Carlisle EJ, Tobe S, Mendelssohn D et al. Left ventricular mean index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125-34.
3. Sasaki R. Bioengineering of recombinant human erythropoietin. In: Jelkmann W editor. Erythropoietin: molecular biology and clinical use. Johnson City, TN: FP Graham Publishing Co; 2002. p. 308-318.
4. Graber SE, Krantz SB. Erythropoietin and the control of red cell production. Annu Rev Med 1978;29:51-66.
5. Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995;83:59-67.
6. Radtke HW, Claussner A, Erbes PH. Serum erythropoietin concentration in chronic renal failure relationship to degree of anemia and excretory renal function. Blood 1979;54:877-84,
7. NKF-DOQI Clinical practice guidelines for the treatment of anemia of chronic renal failure: National Kidney Foundation - Dialysis Outcomes Quality Initiative. Am J Kidney Dis 1997; 30 (4 Suppl 3):S192-240.
8. McMahon LP, Mason K, Skinner SL. Effects of hemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 2000;15:1425-30.
9. Moreno F, Aracil FJ, Perez R, Valderrabnano F. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kidney Dis 1996;27:548-56.
10. Valderrabano F, Horl WH, Jacobs C, Macdougall IC. European Survey on anemia Management (ESAM). Nephrol Dial Transplant 2000;15 Suppl 4:1-76.
11. Double-blind, placebo controlled study of the therapeutic use of recombinant eiythropoietin for anemia associated with chronic renal failure in predialysis patients. The US Recombinant Human Erythropoietin Predialysis Study. Am J Kidney Dis 1991;18:50-9.
12. Revicki D, Brown R, Feeny D. Health-related quality of life associated with recombinant human erythropoietin therapy for pre-dialysis chronic renal disease patients. Am J Kidney Dis 1995;25:548-54.
13. Valderrabano F, on behalf of the Spanish Quality of Live Study Group. Quality of live and Hematocrit in hemodialysis patients. A prospective multicentre study. The 2nd European Epoetin Symposium, 1998, April 17-19, Crete, Greece.
14. Danielson BG. Scandinavian Multicentric Trial. The 2nd European Epoetin Symposium, 1998, April 17-19, Crete, Greece.
15. Foley RN, Parfrey PS, Sarnak MJ. Cardiovascular disease in chronic renal disease: clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32 Suppl 3:5112-9.
16. Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003;41(5 Suppl):11-17.
17. London M, Fabiani F, Marchais SJ. Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. Kidney Int 1987;31:973-80.
18. Katz AM. The cardiomyopathy of overload: an unnatural growth response in hypertrophied heart. Ann Intern Med 1994;121:363-71.
19. Santoro A. Erythropoietin therapy and the cardiovascular system. In: Ronco C, La Greca G editors. Hemodialysis Technology. Contrib Nephrol. Basel: Karger; 2002. p. 137: 1-5.
20. Roy SB, Bhatia ML, Mathur VS. Hemodynamic effects of chronic severe anemia. Circulation 1963;28:346-56.
21. Foley RN, Parfrey PS, Harnett JD. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kid Dis 1996;28:53-61.
22. Besarab A, Bolton WK, Nissenson AR. The normal hematocrit trial in dialysis patients with cardiac disease. Nephrol Dial Transplant 1999;14:2043-4.
23. Macdougall IC, Roberts DE, Coles GA, Williams JD. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet 1991;20:99-113.
24. Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991;50:702-12.
25. Locatelli F, Canaud B, Giacardy F, Martin-Malo A. Baker N, Wilson J. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEPO). Nephrol Dial Transplant 2003;18:362-9.
26. Winearls CG. Recombinant human erythropoietin 10 years of clinic experience. Nephrol Dial Transplant 1998;13 Suppl 2:3-8.
27. Macdougall IC, Cooper A. The inflammatory response and epoetin sensitivity. Nephrol Dial transpl 2002;17 Suppl 1:48-52.
28. Douglas SW, Adamson JW. The anaemia of chronic disorders: studies of marrow regulation and iron metabolism. Blood 1975;45:55-65.
29. European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 1999;14 Suppl 5:1-50.
30. NKF-K-DOQI clinical practice guidelines for anaemia of chronic disease: update 2000. Am J Kidney Dis 2001;37:S182-238.
31. Fisch P, Handgretinger R, Schaefer H-E. Pure red cell aplasia. Br J Haematol 2000;111:1010-22.
32. Casadevall N. Antibodies against r-HuEPO: native and recombinant. Nephrol Dial Transplant 2002;17 Suppl 5:42-7.
33. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-75.
34. Kruger A, Schroer W, Rohrs F, Vescio G. PRCA in a patient treated with epoetin beta. Nephrol Dial Transplant 2003;18:1033-4.
35. Weber G, Gross J, Kromminga A, Loew HH, Eckardt KU. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol 2002;13:2381-3.
36. Eckardt KU, Casadevall N. Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant 2003;18:865-9.
37. Schellenskens H. Immunogenicity of therapeutic proteins. Nephrol Dial Transplant 2003;18:1257-9.
38. Mandreoli M, Finelli C, Lopez A, Ascani S, Vianelli N, Baccarani M et al. Successful resumption of epoetin-alfa after rituximab treatment in a patient with pure red cell aplasia. Am J Kidney Dis 2004;44:757-6l.
39. Zaja F, De Vita S, Russo D, Michelutti A, Fanin R, Ferraccioli G et al. Rituximab for the treatment of type II mixed cryoglobulinemia. Arthritis Rheum 2002;46:2252-4.
40. Macdougall JC. Higher target haemoglobin level and early anaemia treatment: different or complementary concepts? Nephrol Dial Transplant 2000;15 Suppl 3:3-7.
41. Johnson DL, Jolliffe LK. Erythropoietin mimetic peptides and the future. Nephrol Dial Trasplant 2000;15:1274-7.
42. Sytkowski AJ, Lunn ED, Risinger MA, Davis KL. An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties. J Biol Chem 1999;274:24773-8.
43. Osada S, Ebihara I, Setoguchi Y. Gene therapy for renal anemia in mice with polycystic kidney using an adenovirus vector encoding the human erythropoietin gene. Kidney Int 1999;55:1234-40.